Table 1. Correlation of AR polymorphisms with ovarian cancer risk.

Study	Population	Cases/Controls(n)	Findings
CAG repeat polymorphisms
Spurdle et al. (2000)	Australia	319/ 853	No difference between case subjects and control subjects for the smaller, larger or average allele sizes of the CAG(n) genotype, before or after adjusting for age.
Dagan et al. (2002)	Jewish	41/78	No conclusive evidence of association between AR CAG repeat size and ovarian cancer risk in Jewish BRCA1/2 mutation carriers.
Santarosa et al. (2002)	Italy	121/100	An increase in the risk of ovarian cancer in women with CAGn >or=22 and a statistically significant trend towards an increased risk of ovarian cancer with increasing CAGn length.
Terry et al. (2005)	USA	987/1034	Carriage of two alleles with > or = 22 CAG repeats was associated with an increased risk of ovarian cancer compared with carriage of two alleles with <22 CAG repeats.
Schildkraut et al. (2007)	African American, Caucasian	594/681	No relationship observed between CAG repeat length and ovarian cancer among Caucasians, African Americans with a short repeat length on either allele was associated with a 2-fold increase in ovarian cancer risk.
Ludwig et al. (2009)	Poland	215/352	Longer AR (CAG)n repeat tracts decreased the risk of ovarian cancer.
Zhu et al. (2016)	China	1800/1800	Women with longer AR CAG repeats had a decreased EOC risk.
Meng et al. (2015)	China	1925/1900	Women with longer AR CAG repeats had a decreased risk of developing EOC.
GGN repeat polymorphisms
Schildkraut et al. (2007)	African American, Caucasian	594/681	No relationship with the GGC repeat length polymorphisms was observed.
Meng et al. (2015)	China	1925/1900	No significant associations between GGN polymorphism and EOC risk.
Ludwig et al. (2009)	Poland	215/352	Longer AR (GGN)n repeat tracts decreased the risk of ovarian cancer.

AR, androgen receptor; EOC, epithelial ovarian cancer.